LORFAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LORFAN is a small-molecule injectable approved in 1956 by Roche for an undisclosed indication. The mechanism of action and specific therapeutic use are not publicly documented in available data.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a contracting team and reduced commercial investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LORFAN has zero linked job opportunities and is approaching loss of exclusivity, making it a high-risk assignment for career growth. Professionals joining this product should expect resource constraints, sunset planning, and limited advancement potential in a declining franchise.
Brand ManagerField Sales Representative
Worked on LORFAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.